Methodologies, Patient Characteristics, and Treatment Results Between Registry Studies of Botulinum Toxin Type A in Cervical Dystonia (P1.035)

Conclusions: Patient characteristics and response patterns were generally similar across BoNT-A registries, supporting their individual effectiveness in CD.Disclosure: Dr. Trosch has received personal compensation for activities with Ipsen as a speaker and consultant. Dr. Comella has received personal compensation for activities with Ipsen, Merz, Allergan, Medtronic, Teva, US World Meds, Impax, Acadia, Acorda, Revance, Neurocrine, and Ultragenx Pharmaceuticals as a consultant. Dr. Comella has received research support Dr. Espay has received personal compensation as a consultant/scientific advisory board member for Abbvie, Chelsea Therapeutics, TEVA, Impax, Merz, Pfizer, Acadia, Cynapsus, Solstice Neurosciences, Lundbeck, and USWorldMeds; and honoraria from Abbvie, UCB, Dr. Snyder has received personal compensation for activities with Ipsen Biopharmaceuticals. Mr. Marchese has received personal compensation for activities with Ipsen as an employee. Dr. Truong has received personal compensation for activities with Ipsen Biopharmaceuticals, Merz Pharmaceuticals, and Allergan.

Source: Neurology - April 3, 2016 Category: Neurology Authors: Espay, A., Comella, C., Trosch, R., Snyder, D., Marchese, D., Truong, D. Tags: Movement Disorders: Cervical Dystonia Source Type: research